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In This IssueWe are pleased to present the 2012 Special Review Issue of Cell on Human Disease. The motivation for taking on
this broad and complex topic came out of a discussion of how much has changed in the decade since our last
special issue on human disease back in 2001, and how this deeper and richer understanding of biological basis
of disease lays the groundwork for developing new treatments.
Technical breakthroughs, such as high-throughput, sensitive DNA array hybridization and sequencing technolo-
gies, have enabled the detection of single-nucleotide polymorphisms and structural variants genome-wide across
large sample sizes to reveal their associations with disease risk. Related technologies have meanwhile opened
a window onto the complex populations of microbiota within us and their roles in health and disease. Advances
in basic research—such as the achievement of induced pluripotency, understanding plasticity in T cell identity,
and elucidating functions of noncoding RNAs—have opened new avenues for therapeutic development. In other
cases, what was old is now newagain. A decade ago, OttoWarburg’s observations from the 1920s on themetabolic
state of tumor cells had yet to be rediscovered by many cancer researchers.
Reflecting on such seminal advances inspired us to coordinate this special issue, highlighting the exciting new
biology and therapeutic strategies that have emerged from recent discoveries at the bench and in the clinic. We
have tried to cover as many topics as possible while also recognizing the impossibility of achieving completeness
in one issue.We thank themany authors and reviewers who contributed their expertise, time, and effort toward this
collection. We hope that you will find the issue interesting and informative and that it will instill optimism and
impetus for tackling the human biology challenges of the next decade.Decoding Risk
The past decade has seen an explosion in the genetic variants associated
with a multitude of common diseases. What have we learned, and where do
we go from here? A Review from Deepak Srivastava and Sekar Kathiresan
(page 1242) examines the progress in identifying the genetic underpinnings
of cardiovascular disease and the biological insights that may be gleaned
from them. Jonathan Sebat and Dheeraj Malhotra (Review, page 1223)
discuss copy number variations, focusing on those associated with
common psychiatric diseases, such as schizophrenia and bipolar disorder.
They argue that rare variants are likely to account for individual disease risk.
Addressing the role of epigenetics in disease, Elisabet Pujadas and Andrew
Feinberg propose that epigenetic modifications and nuclear architecture
regulate cell plasticity by increasing stochasticity in gene expression
(Perspective, page 1123). They hypothesize that such cellular plasticity and
phenotypic range contributes to
disease susceptibility. This
issue’s Select (page 1073),
written by Laurie Gay of Trendsin Molecular Medicine, highlights recent papers that have yielded insight into
the genetic and epigenetic drivers of pediatric diseases.After Transcription
Besides changes to DNA and chromatin, what else disrupts cellular homeo-
stasis? Cellular dysfunctions occurring in disease contexts often trigger
stress-related signaling responses that are buffered by microRNAs. Joshua
Mendell and Eric Olson explain why thinking about microRNAs from this
perspective helps to elucidate their roles in normal physiology and disease
(Review, page 1172). Splicing defects also feature prominently in a wide variety
of disorders, including muscle atrophy and cancer. Annemieke Aartsma-Rus
and Pietro Spitali present recent clinical and preclinical findings indicating
that a number of diseasesmay be amenable to splice site-modulating therapies
(Minireview, page 1085). Protein aggregation is associated with a number of
pathologies, particularly neurodegeneration. David Eisenberg and Mathias
Jucker (Review, page 1188) review how the molecular properties of prions
and amyloid fibers link to their pathogenicity, and Lennart Mucke and Yadong
Huang (Review, page 1204) share mechanistic insights and diagnostic tech-
niques for the most notorious of amyloid-associated neurodegenerative
diseases, Alzheimer’s.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1069
Energy Matters
As Craig Thompson and Ralph DeBerardinis point out in their Review (page 1132),
‘‘metabolism pervades every aspect of biology.’’ They go on to discuss the insights
that can be gained by examining individuals with genetically encoded metabolic
dysfunction. Using cancer as a paradigm for how metabolic state influences the
course of disease, they delineate how a shift in metabolic pathways contributes to
tumor growth and malignancy. Frances Ashcroft and Patrik Rorsman (Review, page
1160) take on another metabolic disease, diabetes, as they examine how genetic
mutations and environmental factors conspire to cause pancreatic b cell dysfunction,
a driving force in this increasingly common disorder. Mitochondria not only generate
energy and participate in lipid and amino acid metabolism, they also mediate key
cellular events such as apoptosis and intracellular signaling. As such, mitochondrial
dysfunction figures into the pathology of a wide range of diseases, as discussed by
Jodi Nunnari and Anu Suomalainen (Review, page 1145).Influencing Immunity
It goes without saying that our immune system plays a critical role in health, disease, and response to therapies. The interplay
between the innate and adaptive immune systems that maintains balance despite environmental perturbations, and how this
balance is upset, has been a growing area of investigation. Understanding the interactions between two arms of the immune
systemand theenvironmentmayenable us to improve theeffectivenessof various therapies.DouglasGolenbockandStuart Lev-
itz (Review, page 1284) discuss how the innate immune system can be leveraged tomaximize vaccine responses in conjunction
with improved delivery modes. Eliciting both innate and adaptive immune responses is also a strategy for optimizing antibody-
based therapies for cancer, as highlighted by Louis Weiner, Joseph Murray, and Casey Shuptrine (Minireview, page 1081).
The environment tweaks the immune system inmany unexpectedways, particularly fromwithin our own bodies. Ourmicrobiota,
whose complexity is only just coming to light, influence not only our immune systems, but also ourmetabolic capacity. Thus, they
play a critical role in our overall state of health. In their Review, Jose Clemente, Luke Ursell, Laura Parfrey, and Rob Knight (page
1258)postulate thatmovingbeyondcharacterizingmicrobial communities toexamine the interactionsbetweennutrition, immune
cells, and different components of the microbiota will yield greater insight into preventing and treating disease.Coordinating Clinical and Preclinical Progress
Where are we in terms of coordinating efforts in the lab with challenges in the clinic? We asked six physicians working in different
areas of medicine—Anthony Fauci, Laurie Glimcher, Olle Lindvall, Vince Aguirre, Suzanne Topalian, and Kiran Musunuru—how
basic research could most effectively enable them to make progress in treating patients. Their perspectives are shared in this
issue’s Voices (page 1077). The importance of identifying the disease-relevant molecular pathways amenable to therapeutic tar-
geting emerges as one of the themes from their collective comments. New developments in meeting these goals through gener-
ating mammalian models in the lab with ever-increasing efficiency are described by Scott Lowe and Lukas Dow (Review, page
1099). In the same vein, George Daley and Anne Cherry explore how induced pluripotent cells from patients and controls can
be used to model diseases and predict which diseases will be most amenable for this type of modeling (Perspective, page 1110).Drugs, Resistance, and Personalized Medicine
For many conditions, alleviating immediate suffering is equally as important as devel-
oping cures. Irene Tracey’s SnapShot (page 1308) delineates pain pathways and
the ways in which they may be targeted by analgesics. A further challenge in the clinic
is evolved resistance to treatments that initially appear effective. Robert Siliciano, Daniel
Goldberg, andWilliam Jacobs put their heads together to examine what can be learned
from the emergence of drug resistance in diverse pathogens, including those that cause
AIDS, malaria, and tuberculosis (Review, page 1271). Charles Sawyers and Michael
Glickman, in turn, discuss how drug resistance in pathogens can inform our efforts to
surmount acquired chemotherapy resistance of cancer cells (Review, page 1089).
One major challenge to drug efficacy for cancer and other diseases is individual vari-
ability in treatment responses. Gayathri Vaidyanathan investigates the extent to which
geneticmarkers and other biomarkers have been informative for designing clinical trials
and presents different perspectives on pursuing this strategy (Analysis, page 1079).
Finally, in the Resource article included in this issue, Michael Snyder and colleagues
present an example of how personalized medicine may be applied to individuals over
long time frames, analyzing transcription, metabolite, and cytokine fluctuations through
periods of health and disease alongside fully sequenced genomes (page 1293).Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1071
